Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305 were registered as early breast cancer. With broadly application of aromatase inhibitors, hormonal-receptor-positive breast cancer patients can survive longer and longer. However, there is no prevalence of metastatic breast cancer can be available yet. NHIA database coverage is more than 90% population in Taiwan, thus it can be an appropriate surrogate of prevalence. In this retrospective database analysis, we will explore the real world experience on aromatase inhibitor use for breast cancer in Taiwan.
Study Type
OBSERVATIONAL
Enrollment
1
National Cheng Kung University
Tainan, Taiwan
clinical use of aromatase inhibitors in breast cancer
duration of treatment
Time frame: base line, up to 60 months
prevalence
The prevalence of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.
Time frame: base line up to 60 months
dose exposure
The dosage pattern of breast cancer with positive hormonal receptors with routine practice in Taiwan.
Time frame: base line, up to 60 months
overall survival
The overall survival of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.
Time frame: base line, up to 60 months
treatment cost
The treatment cost of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.
Time frame: base line, up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.